A new sublingual tree tablet is currently being developed for the treatment of tree pollen induced allergic rhinoconjunctivitis. Allergic rhinitis is estimated to affect 500 million individuals worldwide and is considered a global health problem. It leads to lower school and work performance. Allergic rhinitis is also a risk factor for asthma development. Currently allergy […]
Ryaltris Nasal Spray for Allergic Rhinitis
Ryaltris is a new nasal spray (formerly GSP301) that is being investigated by Glenmark Pharmaceuticals for the treatment of seasonal allergic rhinitis in patients 12 years and older. Ryaltris consists of 2 drugs, the first one is olopatadine hydrochloride, a nasal antihistamine, which is the medication used in Patanase nasal spray. The second medication […]
Nasonex OTC coming soon
Nasonex OTC will soon be available without a prescription. Perrigo Company announced today that it has entered into a licensing agreement with Merck (the manufacturer of Nasonex) for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, Nasonex OTC (mometasone furoate monohydrate) Nasal Spray. Nasonex is currently available by prescription […]
Do antibiotics or acid suppressor meds in infants promote allergy?
The use of antibiotics and acid suppressor medications can cause changes the gut flora. Changes in the microbes can increase the risk of allergic diseases. A recent study looked into the use of antibiotics or acid suppressive medications. Histamine 2 receptor antagonists, i.e. Zantac (ranitidine) or proton pump inhibitors, Prilosec (omeprazole), within the first 6 […]
Xhance for Nasal Polyps
Xhance is a new nasal spray to be available April 2018. Xhance is indicated for the the treatment of nasal polyps in patients 18 years or older. The active ingredient in Xhance is fluticasone propionate 93 mcg. If that sounds familiar, fluticasone propionate is the active ingredient in Flonase. What is different from Xhance from […]
Mepolizumab (Nucala) for Nasal Polyps
Mepolizumab (Nucala), an IL-5 antibody was approved in the past for patients who have severe persistent asthma. New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma A recent study sought to determine whether mepolizumab could reduce the need for surgery in patients with severe recurrent bilateral nasal polyps. Chronic sinusitis is common, and it can […]
Do nasal steroids help asthma?
Chronic nasal sinus disease is common in asthma and it is associated with poor asthma control. A recent study showed that intranasal steroids does not help poorly controlled asthma over 24 weeks. It was hypothesized that the intranasal corticosteroids might decrease airway markers of allergic inflammation with chronic treatment, and also improve asthma control specifically […]
Allergy Biologics, Past, Present and Future…
The world of allergy biologics has exploded in the last year. New biologic agents are being developed that target specific and critical pathways to help manage patients who have asthma, hives, eczema and nasal polyps. Here I will focus on allergy biologics already approved for management of asthma and allergies as well as allergy biologics […]
Generic Advair Availability is Delayed
Update January 30, 2019 The FDA just approved generic Advair and it should be available in the coming weeks. Mylan has not indicated the price on it yet but the hope is that it will be significantly cheaper than the branded version. It is anticipated that insurance companies will now require for patients to use […]
Nemolizumab for Itching and Atopic Dermatitis
Nemolizumab is a new medication being currently developed by Chugai Pharmaceutical Company. It will be licensed and developed by Galderma Pharma who picked up the rights to it. With the recent ground breaking FDA approval of Dupixent (dupilumab) for eczema, this will help many patients suffering itchy, inflamed dry skin. As with all new biological […]